Crescent Biologicals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 2.71 M
- Revenue Growth -32.95%
- Profit Growth -93.00%
- Ebitda -92.61%
- Net Worth 5.87%
- Total Assets 272.34%
About Crescent Biologicals
Crescent Biologicals Private Limited (CBPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 August 2017 (Seven years and five months 29 days old ). Its registered office is in Vellore, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹2.71 M.
Prabhavathi Premkumar and Raman Sudha serve as directors at the Company.
Company Details
-
Location
Vellore, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24304TN2017PTC118045
-
Company No.
118045
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Aug 2017
-
Date of AGM
29 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Crescent Biologicals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prabhavathi Premkumar
|
Director | 09-Aug-2017 | Current |
|
Raman Sudha
|
Director | 21-Mar-2019 | Current |
Financial Performance of Crescent Biologicals.
Crescent Biologicals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 32.95% decrease. The company also saw a substantial fall in profitability, with a 93% decrease in profit. The company's net worth moved up by a moderate rise of 5.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Crescent Biologicals?
In 2022, Crescent Biologicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Bu Agrotech Private LimitedPrabhavathi Premkumar is a mutual person
-
Floral Granites Private Limited
Prabhavathi Premkumar and Raman Sudha are mutual person
Charges (Loans)
₹2.71 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.27 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Nov 2022 | Others | ₹2.71 M | Open |
How Many Employees Work at Crescent Biologicals?
Unlock and access historical data on people associated with Crescent Biologicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Crescent Biologicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Crescent Biologicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
